Departamento de Biotecnologia em Plantas Medicinais, Universidade de Ribeirão Preto, 14096-900, Ribeirão Preto, SP, Brazil.
Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, 14049-900, Ribeirão Preto, SP, Brazil.
J Ethnopharmacol. 2024 Jan 30;319(Pt 2):117255. doi: 10.1016/j.jep.2023.117255. Epub 2023 Sep 29.
ETHNOPHARMACOLOGICAL RELEVANCE: Crocus sativus L. (saffron, Iridaceae) has been traditionally used for thousands of years as herbal medicine for many diseases, including type-2 diabetes mellitus (T2DM), especially in Sri Lanka. Systematic reviews and meta-analysis on C. sativus for T2DM value traditional knowledge about this species. AIM OF THE STUDY: To assess the effectiveness of C. sativus powdered plant, hydroethanolic extract and crocin in reducing fasting blood sugar (FBG), glycated hemoglobin (HbA1c), blood pressure, and other metabolic parameters in patients with T2DM. MATERIAL AND METHODS: Systematic review and meta-analysis based on searches in PubMed, Embase, and Cochrane, including all randomized clinical trials (RCTs) published before January 2, 2023. Two independent reviewers extracted the data and assessed the risks of bias. The effects of C. sativus and crocin were assessed on glycemic, metabolic, and blood pressure parameters. Weighted (WMD) or standardized (SMD) mean differences (before-after) and 95% confidence intervals (95%CI) of the outcomes were extracted or estimated and meta-analyses were conducted using RevMan 5.4 (Cochrane Collaboration). This protocol was registered in PROSPERO (#CRD42023390073). RESULTS: Fifteen of 29 studies were included. Saffron powdered plant decreased AST (WMD -1.19, 95%CI -2.24, -0.13), but increased BMI (WMD 0.56, 95%CI 0.07, 1.05); saffron extract decreased HbA1c (WMD -0.35, 95%CI -0.65, -0.06), FBG (WMD -26.90, 95%CI -38.87, -14.93), creatinine (WMD -0.12, 95%CI -0.19, -0.05), and total cholesterol (WMD -9.29, 95%CI -18.25, -0.33); and crocin decreased HbA1c (WMD -0.43, 95%CI -0.66, -0.20), FBG (WMD -14.10, 95%CI -22.91, -5.30), and systolic blood pressure (WMD -8.18, 95%CI -12.75, -3.61), but increased creatinine levels (WMD 0.24, 95%CI 0.17, 0.32). Of the 15 included studies, 14 had a moderate risk of bias, and one study had a low risk of bias. CONCLUSION: C. sativus (saffron) powdered plant, extract, and crocin have potential as an adjunct treatment for T2DM, improving control of metabolic and clinical parameters. However, C. sativus extract seems to be superior because it was effective in more parameters and did not induce adverse effects. Since many studies were at moderate risk of bias, further high-quality research is needed to firmly establish the clinical efficacy of this plant.
民族药理学相关性:藏红花(藏红花,鸢尾科)数千年来一直被传统用作治疗多种疾病的草药,包括 2 型糖尿病(T2DM),尤其是在斯里兰卡。系统评价和荟萃分析表明,藏红花对 T2DM 的价值与该物种的传统知识有关。
研究目的:评估藏红花粉植物、水醇提取物和藏红花酸在降低 T2DM 患者空腹血糖(FBG)、糖化血红蛋白(HbA1c)、血压和其他代谢参数方面的有效性。
材料和方法:基于在 PubMed、Embase 和 Cochrane 中进行的搜索,进行系统评价和荟萃分析,包括 2023 年 1 月 2 日之前发表的所有随机临床试验(RCT)。两名独立评审员提取数据并评估偏倚风险。评估藏红花和藏红花酸对血糖、代谢和血压参数的影响。提取或估计(前后)加权(WMD)或标准化(SMD)均值差异和 95%置信区间(95%CI),并使用 RevMan 5.4(Cochrane 协作)进行荟萃分析。该方案已在 PROSPERO(#CRD42023390073)中注册。
结果:29 项研究中有 15 项被纳入。藏红花粉植物降低 AST(WMD-1.19,95%CI-2.24,-0.13),但增加 BMI(WMD 0.56,95%CI 0.07,1.05);藏红花提取物降低 HbA1c(WMD-0.35,95%CI-0.65,-0.06)、FBG(WMD-26.90,95%CI-38.87,-14.93)、肌酐(WMD-0.12,95%CI-0.19,-0.05)和总胆固醇(WMD-9.29,95%CI-18.25,-0.33);藏红花酸降低 HbA1c(WMD-0.43,95%CI-0.66,-0.20)、FBG(WMD-14.10,95%CI-22.91,-5.30)和收缩压(WMD-8.18,95%CI-12.75,-3.61),但升高肌酐水平(WMD 0.24,95%CI 0.17,0.32)。在纳入的 15 项研究中,14 项研究的偏倚风险为中度,1 项研究的偏倚风险为低度。
结论:藏红花(藏红花)粉植物、提取物和藏红花酸具有作为 T2DM辅助治疗的潜力,可改善代谢和临床参数的控制。然而,藏红花提取物似乎更有效,因为它在更多的参数上有效,并且没有引起不良反应。由于许多研究存在中度偏倚风险,因此需要进一步进行高质量的研究,以确定该植物的临床疗效。
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2020-1-9
Health Technol Assess. 2010-7
Cochrane Database Syst Rev. 2020-10-19
Cochrane Database Syst Rev. 2018-9-24
Cochrane Database Syst Rev. 2025-6-16
Health Technol Assess. 2024-10